{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:51Z","timestamp":1761512751974},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T00:00:00Z","timestamp":1260230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to investigate the effect of long\u2010term high\u2010physiological\u2010dose recombinant human growth hormone (rhGH) therapy on fat distribution and glucose metabolism in HIV\u2010infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty\u2010six HIV\u2010infected Caucasian men on highly active antiretroviral therapy (HAART), with an age range of 21\u201360 years and no significant comorbidity, were included in this randomized, placebo\u2010controlled, double\u2010blind, single\u2010centre trial. Twenty\u2010eight subjects were randomized to 0.7\u2003mg\/day rhGH, and 18 subjects to placebo, administered as daily subcutaneous injections between 1 and 3 pm for 40 weeks. Endpoints included changes in visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), limb fat mass, percentage of limb fat, plasma lipids, insulin resistance and glucose tolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>VAT and trunk fat mass decreased significantly in the GH group compared with the placebo group [\u221219\u2003cm<jats:sup>2<\/jats:sup> (\u221211%) <jats:italic>vs<\/jats:italic>. 12\u2003cm<jats:sup>2<\/jats:sup> (6%), <jats:italic>P<\/jats:italic>=0.03, and \u2212548\u2003g (\u22129%) <jats:italic>vs<\/jats:italic>. 353\u2003g (6%), <jats:italic>P<\/jats:italic>&lt;0.01, respectively]. The beneficial fat redistribution in the GH group occurred without concomitant changes in subcutaneous fat at the abdomen or extremities. rhGH therapy was well tolerated. Insulin resistance, glucose tolerance, and total plasma cholesterol and triglycerides did not significantly change during intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Daily 0.7\u2003mg rhGH treatment for 40 weeks reduced abdominal visceral fat and trunk fat mass in HIV\u2010infected patients. This treatment appeared to be safe with respect to glucose tolerance and insulin sensitivity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00775.x","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T13:35:46Z","timestamp":1260279346000},"page":"266-275","source":"Crossref","is-referenced-by-count":9,"title":["Long\u2010term high\u2010physiological\u2010dose growth hormone reduces intra\u2010abdominal fat in HIV\u2010infected patients with a neutral effect on glucose metabolism"],"prefix":"10.1111","volume":"11","author":[{"given":"BR","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SB","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FK","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JEB","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1482","article-title":"Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection","volume":"31","author":"Thiebaut R","year":"2000","journal-title":"Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_7_4_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"Carr A","year":"2003","journal-title":"a case-control study"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00201-4"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200403010-00004"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.8.3480"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.2.942"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-199910220-00013","article-title":"Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV","volume":"13","author":"Wanke C","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_7_10_2","unstructured":"MoyleG BaldwinC LangroudiB GazzardB.Growth hormone improves appearance and lean mass in lipoatrophic patients and these benefits are maintained with alternate day dosing Abstract H. 1935. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 2002 San Diego USA."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200208010-00002"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.3.727"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.504"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410021162"},{"key":"e_1_2_7_15_2","first-page":"781","article-title":"GH treatment reduces trunkal adiposity in HIV\u2010infected patients with lipodystrophy","volume":"153","author":"Luzi L","year":"2005","journal-title":"a randomized placebo-controlled study"},{"key":"e_1_2_7_16_2","first-page":"509","article-title":"Low\u2010dose physiological growth hormone in patients with HIV and abdominal fat accumulation","volume":"300","author":"Lo J","year":"2008","journal-title":"a randomized controlled trial"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.08.025"},{"key":"e_1_2_7_18_2","first-page":"561","article-title":"Low\u2010dose growth hormone and human immunodeficiency virus\u2010associated lipodystrophy syndrome","volume":"34","author":"Andersen O","year":"2004","journal-title":"a pilot study"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02223.x"},{"key":"e_1_2_7_20_2","first-page":"169","article-title":"Non\u2010competitive time\u2010resolved immunofluorometric assays for determination of human insulin\u2010like growth factor I and II","volume":"5","author":"Frystyk J","year":"1995","journal-title":"Growth Regul"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0838.1995.tb00027.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072375"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-11-199612010-00002"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404010-00006"},{"key":"e_1_2_7_25_2","unstructured":"AbergJA ZackinRA EvansSRet al. A prospective multi\u2010center randomized trial comparing the efficacy and safety of fenofibrate vs pravastatin in HIV\u2010infected subjects with lipid abnormalities: final results of ACTG 5087. 11th Conference on Retroviruses and Opportunistic Infections February 2004 San Francisco USA."},{"key":"e_1_2_7_26_2","first-page":"207","article-title":"Evening versus morning injections of growth hormone (GH) in GH\u2010deficient patients","volume":"70","author":"Jorgensen JO","year":"1990","journal-title":"effects on 24-hour patterns of circulating hormones and metabolites"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.11.4028"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00775.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00775.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:41:37Z","timestamp":1698673297000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00775.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00775.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00775.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}